Approximately 4 million Americans and 170 million people worldwidesuffer from hepatitis C, a viral liver disease that is treatablebut not curable. It accounts for more than 40 percent of U.S. liverdisease deaths-about 8,000 to 10,000 people annually-and is themost common reason for liver transplantation. This compassionateguide explains how hepatitis C affects the liver and the body andprovides solid advice on today's treatment options-from drugs (andtheir side effects) to transplants and alternative therapies-aswell as tips on dealing with the emotional and financial burdensthe disease brings with it.
Nina L Paul, PhD (New York, NY) earned her doctorate in infectiousdisease epidemiology and immunology from Yale University. She hasresearched viruses (human immunodeficiency virus and others) andthe immune system.